The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Americans love their Star-Spangled Banner, the French are obsessed with national pride but we Brits have a patriotism problem ...

AstraZeneca's lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank. The ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...

A Phase 3 trial found AstraZeneca's experimental lung cancer drug did not significantly improve patients' overall survival rates.

“As a company driven by science and patient-centricity, AstraZeneca stands in full support of this ... He said he hoped that ...